Roger Susi Sells 2,500 Shares of iRadimed (NASDAQ:IRMD) Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of the business’s stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $94.84, for a total value of $237,100.00. Following the sale, the chief executive officer owned 2,217,500 shares in the company, valued at approximately $210,307,700. The trade was a 0.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Performance

iRadimed stock opened at $97.33 on Thursday. The business’s 50-day simple moving average is $99.49 and its two-hundred day simple moving average is $91.94. The company has a market cap of $1.24 billion, a PE ratio of 55.62 and a beta of 1.11. iRadimed Corporation has a fifty-two week low of $47.48 and a fifty-two week high of $107.90.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.05. The business had revenue of $22.69 million for the quarter, compared to the consensus estimate of $21.60 million. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, analysts predict that iRadimed Corporation will post 1.66 EPS for the current fiscal year.

iRadimed Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.8%. The ex-dividend date was Monday, February 23rd. This is a boost from iRadimed’s previous quarterly dividend of $0.17. iRadimed’s dividend payout ratio (DPR) is presently 45.71%.

Institutional Trading of iRadimed

A number of hedge funds have recently modified their holdings of the stock. CWM LLC boosted its stake in shares of iRadimed by 19.5% in the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after buying an additional 107 shares during the last quarter. Johnson Investment Counsel Inc. boosted its stake in shares of iRadimed by 0.7% in the third quarter. Johnson Investment Counsel Inc. now owns 25,842 shares of the medical equipment provider’s stock worth $1,839,000 after buying an additional 187 shares during the last quarter. Summit Global Investments boosted its stake in shares of iRadimed by 2.7% in the third quarter. Summit Global Investments now owns 7,139 shares of the medical equipment provider’s stock worth $508,000 after buying an additional 188 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of iRadimed by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after buying an additional 234 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of iRadimed by 4.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,824 shares of the medical equipment provider’s stock worth $567,000 after buying an additional 267 shares during the last quarter. Hedge funds and other institutional investors own 92.34% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on IRMD shares. Lake Street Capital reiterated a “buy” rating and set a $120.00 price target on shares of iRadimed in a research note on Wednesday, February 11th. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Roth Mkm reiterated a “buy” rating and set a $120.00 price target on shares of iRadimed in a research note on Tuesday, February 10th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, iRadimed presently has a consensus rating of “Buy” and an average price target of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.